Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
0.7412
-0.0187 (-2.46%)
Apr 21, 2025, 4:00 PM EDT - Market closed
Opus Genetics Employees
Opus Genetics had 18 employees as of December 31, 2024. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
$610,667
Profits / Employee
-$3,196,222
Market Cap
33.71M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 4 | 28.57% |
| Dec 31, 2023 | 14 | 5 | 55.56% |
| Dec 31, 2022 | 9 | 1 | 12.50% |
| Dec 31, 2021 | 8 | 3 | 60.00% |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
IRD News
- 10 days ago - Founder Mina Sooch Issues Open Letter to Opus Genetics Stockholders Following Withdrawal of the Restore Value Slate Amid Dilutive Financing and Governance Concerns - GlobeNewsWire
- 13 days ago - Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases - GlobeNewsWire
- 19 days ago - Opus Genetics to Participate in Upcoming Investor Conference in April - GlobeNewsWire
- 21 days ago - Opus Genetics Announces Financial Results for Full Year 2024 - GlobeNewsWire
- 4 weeks ago - Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics - GlobeNewsWire
- 4 weeks ago - Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX - GlobeNewsWire
- 4 weeks ago - Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million - GlobeNewsWire
- 4 weeks ago - Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire